{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:11:20Z","timestamp":1778883080540,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:00:00Z","timestamp":1794268800000},"content-version":"am","delay-in-days":558,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100017003","name":"Peking University Health Science Center","doi-asserted-by":"publisher","award":["P30CA046592"],"award-info":[{"award-number":["P30CA046592"]}],"id":[{"id":"10.13039\/501100017003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["L30 CA264387"],"award-info":[{"award-number":["L30 CA264387"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["L30 CA264387"],"award-info":[{"award-number":["L30 CA264387"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32 CA180984"],"award-info":[{"award-number":["T32 CA180984"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006280","name":"Urology Care Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006280","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007270","name":"University of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021763","name":"American Urological Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021763","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000867","name":"Robert Wood Johnson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000867","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.euf.2025.04.022","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T17:07:54Z","timestamp":1745341674000},"page":"417-420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Defining the Role of Surgical Resection in Metastatic Renal Cell Carcinoma: A Mini Review"],"prefix":"10.1016","volume":"11","author":[{"given":"Steven M.","family":"Monda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simpa S.","family":"Salami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulka","family":"Vaishampayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd M.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udit","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2025.04.022_b0005","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa003013","article-title":"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer","volume":"345","author":"Flanigan","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.04.022_b0010","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0140-6736(01)06103-7","article-title":"European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial","volume":"358","author":"Mickisch","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2025.04.022_b0015","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.04.022_b0020","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamaoncol.2018.5543","article-title":"Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial","volume":"5","author":"Bex","year":"2019","journal-title":"JAMA Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.euf.2025.04.022_b0025","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2019.37.15_suppl.4508","article-title":"Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): update on Carmena trial with focus on intermediate IMDC-risk population","volume":"37","author":"Mejean","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.04.022_b0030","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/jnci\/djae066","article-title":"Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a US Food and Drug Administration pooled analysis","volume":"116","author":"Fallah","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euf.2025.04.022_b0035","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.euo.2018.08.028","article-title":"Surgical metastasectomy in renal cell carcinoma: a systematic review","volume":"2","author":"Ouzaid","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2025.04.022_b0040","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/JU.0000000000000488","article-title":"Complete surgical metastasectomy of renal cell carcinoma in the post-cytokine era","volume":"203","author":"Lyon","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.04.022_b0045","doi-asserted-by":"crossref","first-page":"937.e1","DOI":"10.1016\/j.urolonc.2020.08.017","article-title":"Pushing the limits of metastasis-directed treatment in metastatic renal cell carcinoma in the era of targeted therapy","volume":"38","author":"Holz","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2025.04.022_b0050","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.clgc.2022.03.010","article-title":"Benefit of metastasectomy in renal cell carcinoma: a propensity score analysis","volume":"20","author":"Maisel","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euf.2025.04.022_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102018","article-title":"Metastatic renal cell carcinoma to the pancreas and other sites\u2014a multicenter retrospective study","volume":"60","author":"Duarte","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.euf.2025.04.022_b0060","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2013.08.012","article-title":"Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy","volume":"65","author":"McKay","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.04.022_b0065","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"issue":"6 Suppl","key":"10.1016\/j.euf.2025.04.022_b0070","article-title":"SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer","volume":"40","author":"Vaishampayan","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.04.022_b0075","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12885-024-11987-3","article-title":"Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-trial","volume":"24","author":"Iisager","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euf.2025.04.022_b0080","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant\u2013adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.04.022_b0085","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(21)00528-3","article-title":"Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial","volume":"22","author":"Tang","year":"2021","journal-title":"Lancet Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.euf.2025.04.022_b0090","article-title":"NRG-GU012: Randomized phase II stereotactic ablative radiation therapy (SABR) for patients with metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI)","volume":"41","author":"Hall","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.euf.2025.04.022_b0095","article-title":"Phase III randomized trial of stereotactic ablative radiotherapy (SAbR) for oligometastatic advanced renal carcinoma (EA8211-SOAR)","volume":"42","author":"Hannan","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925000987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925000987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:37:03Z","timestamp":1778881023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456925000987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2405456925000987"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2025.04.022","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Defining the Role of Surgical Resection in Metastatic Renal Cell Carcinoma: A Mini Review","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2025.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}